Polymorphisms in genes controlling inflammation and tissue repair in rheumatoid arthritis: A case control study

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Emonts, Marieke ^a,b,g   Hazes, Mieke J M W ^a   Houwing Duistermaat, Jeanine J ^c   van der Gaast de Jongh, Christa E ^b,d   de Vogel, Lisette ^a,b   Han, Huub K H ^e   Wouters, Jacques M G W ^f   Laman, Jon D ^a   Dolhain, Radboud J E M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Maasstad Hospital   (Netherlands)

^f SINT FRANCISCUS GASTHUIS   (Netherlands)

^g NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT INHIBITOR 1; COMPLEMENT INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; AUTACOID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA ISOLATION; FEMALE; GENE CONTROL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RHEUMATOID ARTHRITIS; TISSUE REPAIR; AGED; CASE CONTROL STUDY; COHORT ANALYSIS; GENETICS; HOSPITALIZATION; MIDDLE AGED; ONSET AGE;

ADULT; AGE OF ONSET; AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; COHORT STUDIES; GENOTYPE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-8; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952322216     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-36     Document Type: Article

References (55)

1. van den Berg WB. Arguments for interleukin 1 as a target in chronic arthritis. Ann Rheum Dis 2000, 59(Suppl 1):i81-84. 10.1136/ard.59.suppl_1.i81, 1766623, 11053095.
2. Zwerina J, Redlich K, Schett G, Smolen JS. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 2005, 1051:716-729. 10.1196/annals.1361.116, 16127012.
3. Heinzmann A, Ahlert I, Kurz T, Berner R, Deichmann KA. Association study suggests opposite effects of polymorphisms within IL8 on bronchial asthma and respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2004, 114:671-676. 10.1016/j.jaci.2004.06.038, 15356575.
4. Rodenburg RJ, van Den Hoogen FH, Barrera P, van Venrooij WJ, van De Putte LB. Superinduction of interleukin 8 mRNA in activated monocyte derived macrophages from rheumatoid arthritis patients. Ann Rheum Dis 1999, 58:648-652. 10.1136/ard.58.10.648, 1752770, 10491366.
5. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994, 56:559-564.
6. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54:2817-2829. 10.1002/art.22033, 16947782.
7. Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, van den Berg WB. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res 1999, 1:81-91. 10.1186/ar14, 17779, 11056663.
8. Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998, 24:629-639. 10.1016/S0889-857X(05)70030-2, 9710891.
9. Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, Czipri M, Mikecz K, Zhang J. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J Immunol 2002, 169:3345-3352.
10. Prots I, Skapenko A, Wendler J, Mattyasovszky S, Yone CL, Spriewald B, Burkhardt H, Rau R, Kalden JR, Lipsky PE, Schulze-Koops H. Association of the IL4R single-nucleotide polymorphism I50V with rapidly erosive rheumatoid arthritis. Arthritis Rheum 2006, 54:1491-1500. 10.1002/art.21832, 16646030.
11. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997, 232:420-429. 10.1006/excr.1997.3540, 9168821.
12. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996, 383:441-443. 10.1038/383441a0, 8837777.
13. Li J, Guo Y, Holmdahl R, Ny T. Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. Arthritis Rheum 2005, 52:2541-2548. 10.1002/art.21229, 16052596.
14. Criswell LA, Gregersen PK. Current understanding of the genetic aetiology of rheumatoid arthritis and likely future developments. Rheumatology (Oxford) 2005, 44(Suppl 4):iv9-iv13. 10.1093/rheumatology/kei054, 16306485.
15. Gibert M, Balandraud N, Touinssi M, Mercier P, Roudier J, Reviron D. Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: the protective effect. Hum Immunol 2003, 64:930-935. 10.1016/S0198-8859(03)00186-1, 14522089.
16. Tamiya G, Shinya M, Imanishi T, Ikuta T, Makino S, Okamoto K, Furugaki K, Matsumoto T, Mano S, Ando S, et al. Whole genome association study of rheumatoid arthritis using 27 039 microsatellites. Hum Mol Genet 2005, 14:2305-2321. 10.1093/hmg/ddi234, 16000323.
17. Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Gibbons L, Plant D, Wilson AG, Marinou I, et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum Mol Genet 2008, 17:2274-2279. 10.1093/hmg/ddn128, 2465799, 18434327.
18. Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Plant D, Gibbons LJ, Wilson AG, Bax DE, et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet 2008, 40:1156-1159. 10.1038/ng.218, 2662493, 18794857.
19. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30:1205-1213. 10.1002/art.1780301102, 2446635.
20. Hinks A, Worthington J, Thomson W. The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis. Rheumatology (Oxford) 2006, 45:365-368. 10.1093/rheumatology/kel005, 16418195.
21. Orozco G, Hinks A, Eyre S, Ke X, Gibbons LJ, Bowes J, Flynn E, Martin P, Wilson AG, Bax DE, et al. Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum Mol Genet 2009, 18:2693-2699. 10.1093/hmg/ddp193, 2701332, 19417005.
22. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FA, Zhernakova A, Hinks A, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010, 42:508-514. 10.1038/ng.582, 20453842.
23. Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, Donn R, Symmons D, Hider S, Bruce IN, et al. Rheumatoid arthritis association at 6q23. Nat Genet 2007, 39:1431-1433. 10.1038/ng.2007.32, 2674282, 17982455.
24. Orozco G, Barton A. Update on the genetic risk factors for rheumatoid arthritis. Expert Rev Clin Immunol 2010, 6:61-75. 10.1586/eci.09.72, 20383892.
25. Nakashima H, Miyake K, Inoue Y, Shimizu S, Akahoshi M, Tanaka Y, Otsuka T, Harada M. Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 2002, 3:107-109. 10.1038/sj.gene.6363830, 11960309.
26. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376. 10.1172/JCI2629, 508984, 9769329.
27. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993, 268:10739-10745.
28. Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K, Hu JJ. The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 2004, 64:6344-6348. 10.1158/0008-5472.CAN-04-0338, 15342424.
29. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997, 24:1-8. 10.1111/j.1365-2370.1997.tb00001.x, 9043871.
30. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C, Rogus J, Beck JD, Offenbacher S, Cork MJ, et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 2006, 15:519-529. 10.1093/hmg/ddi469, 16399797.
31. Wen AQ, Wang J, Feng K, Zhu PF, Wang ZG, Jiang JX. Effects of haplotypes in the interleukin 1beta promoter on lipopolysaccharide-induced interleukin 1beta expression. Shock 2006, 26:25-30. 10.1097/01.shk.0000223125.56888.c7, 16783194.
32. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999, 354:556-560. 10.1016/S0140-6736(99)02220-5, 10470700.
33. Correa PA, Gomez LM, Cadena J, Anaya JM. Autoimmunity and tuberculosis. Opposite association with TNF polymorphism. J Rheumatol 2005, 32:219-224.
34. Hull J, Ackerman H, Isles K, Usen S, Pinder M, Thomson A, Kwiatkowski D. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet 2001, 69:413-419. 10.1086/321291, 1235312, 11431705.
35. Rodriguez-Carreon AA, Zuniga J, Hernandez-Pacheco G, Rodriguez-Perez JM, Perez-Hernandez N, Montes de Oca JV, Cardiel MH, Granados J, Vargas-Alarcon G. Tumor necrosis factor-alpha -308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in Mexicans. J Autoimmun 2005, 24:63-68. 10.1016/j.jaut.2004.11.002, 15725578.
36. van de Geijn FE, Roos A, de Man YA, Laman JD, de Groot CJ, Daha MR, Hazes JM, Dolhain RJ. Mannose-binding lectin levels during pregnancy: a longitudinal study. Hum Reprod 2007, 22:362-371. 10.1093/humrep/del392, 17099209.
37. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet 2004, 68:165-177. 10.1046/j.1529-8817.2003.00085.x, 15008795.
38. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002, 70:425-434. 10.1086/338688, 384917, 11791212.
39. QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies. , http://hydra.usc.edu/gxe
40. Klimiuk PA, Sierakowski S, Latosiewicz R, Skowronski J, Cylwik JP, Cylwik B, Chwiecko J. Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1666-1672.
41. Lo SF, Huang CM, Lin HC, Chen WC, Tsai CH, Tsai FJ. Cytokine (IL-6) and chemokine (IL-8) gene polymorphisms among rheumatoid arthritis patients in Taiwan. Clin Exp Rheumatol 2008, 26:632-637.
42. Khanna D, Wu H, Park G, Gersuk V, Gold RH, Nepom GT, Wong WK, Sharp JT, Reed EF, Paulus HE, Tsao BP. Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum 2006, 54:1105-1116. 10.1002/art.21750, 16572445.
43. Balog A, Klausz G, Gal J, Molnar T, Nagy F, Ocsovszky I, Gyulai Z, Mandi Y. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 2004, 71:274-280. 10.1159/000080062, 15459487.
44. Seitz M, Wirthmuller U, Moller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2006,
45. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003, 48:1849-1852. 10.1002/art.11168, 12847678.
46. Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms?. Genes Immun 2004, 5:315-329. 10.1038/sj.gene.6364055, 14973548.
47. Lindberg J, Af Klint E, Ulfgren AK, Stark A, Andersson T, Nilsson P, Klareskog L, Lundeberg J. Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther 2006, 8:R47. 10.1186/ar1903, 1526587, 16507157.
48. Martinez A, Pascual M, Pascual-Salcedo D, Balsa A, Martin J, de la Concha EG. Genetic polymorphisms in Spanish rheumatoid arthritis patients: an association and linkage study. Genes Immun 2003, 4:117-121. 10.1038/sj.gene.6363931, 12618859.
49. Riyazi N, Kurreeman FA, Huizinga TW, Dekker FW, Stoeken-Rijsbergen G, Kloppenburg M. The role of interleukin 10 promoter polymorphisms in the susceptibility of distal interphalangeal osteoarthritis. J Rheumatol 2005, 32:1571-1575.
50. Ates O, Hatemi G, Hamuryudan V, Topal-Sarikaya A. Tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. Clin Rheumatol 2008, 27:1243-1248. 10.1007/s10067-008-0893-1, 18427872.
51. Schluter B, Raufhake C, Erren M, Schotte H, Kipp F, Rust S, Van AH, Assmann G, Berendes E. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002, 30:32-37. 10.1097/00003246-200201000-00005, 11902285.
52. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000, 275:18138-18144. 10.1074/jbc.M000379200, 10747905.
53. Hegedus CM, Skibola CF, Bracci P, Holly EA, Smith MT. Screening the human serum proteome for genotype-phenotype associations: an analysis of the IL6 - 174G > C polymorphism. Proteomics 2007, 7:548-557. 10.1002/pmic.200600366, 17309100.
54. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003, 62:635-638. 10.1136/ard.62.7.635, 1754593, 12810425.
55. Kuuliala K, Orpana A, Leirisalo-Repo M, Kautiainen H, Hurme M, Hannonen P, Korpela M, Mottonen T, Paimela L, Puolakka K, et al. Polymorphism at position +896 of the toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. Ann Rheum Dis 2006, 65:1241-1243. 10.1136/ard.2006.055137, 1798301, 16606645.